Pravastatin ( DrugBank: Pravastatin )

---

9 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	1
46	悪性関節リウマチ	3
49	全身性エリテマトーデス	1
67	多発性嚢胞腎	3
79	家族性高コレステロール血症（ホモ接合体）	1
96	クローン病	1
164	眼皮膚白皮症	1
265	脂肪萎縮症	3
333	ハッチンソン・ギルフォード症候群	3

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,342 /  薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00200655 (ClinicalTrials.gov)	December 2004	12/9/2005	Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis	Safety and Efficacy of Pravastatin in Relapsing-remitting MS: a Double Blind Placebo Controlled Study	Relapsing-remitting Multiple Sclerosis	Drug: Pravastatin;Drug: Placebo	Nantes University Hospital	NULL	Completed	18 Years	45 Years	Both	40	Phase 3	France

46. 悪性関節リウマチ

---

臨床試験数 : 4,325 /  薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04608344 (ClinicalTrials.gov)	November 4, 2020	23/10/2020	Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants	A Phase 1 Study to Evaluate OATP Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants	Rheumatoid Arthritis	Drug: Atorvastatin;Drug: Pravastatin;Drug: Rosuvastatin;Drug: Filgotinib	Gilead Sciences	Galapagos NV	Completed	18 Years	55 Years	All	27	Phase 1	United States
2	NCT03131973 (ClinicalTrials.gov)	May 13, 2017	25/4/2017	Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin	Effects of Concomitant Administration of BMS-986195 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates for Cytochrome P450 1A2, 2C8, 2C9, 2C19, 3A4, Organic Anion Transporter Polypeptide 1B1 and P-glycoprotein in Healthy Participants	Rheumatoid Arthritis	Drug: BMS-986195;Drug: Methotrexate;Drug: Leucovorin;Drug: Caffeine;Drug: Montelukast;Drug: Flurbiprofen;Drug: Omeprazole;Drug: Midazolam;Drug: Digoxin;Drug: Pravastatin	Bristol-Myers Squibb	NULL	Completed	18 Years	50 Years	All	26	Phase 1	United States
3	NCT02456844 (ClinicalTrials.gov)	May 2015	27/5/2015	Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients	Effects of BMS-986142 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates Montelukast (CYP2C8), Flurbiprofen (CYP2C9), Midazolam (CYP3A4), Digoxin (P-gp), and Pravastatin (OATP1B1) in Healthy Subjects	Rheumatoid Arthritis	Drug: Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142;Drug: Methotrexate, Leucovorin and BMS-986142	Bristol-Myers Squibb	NULL	Completed	18 Years	50 Years	Both	24	Phase 1	NULL

49. 全身性エリテマトーデス

---

臨床試験数 : 946 /  薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00054938 (ClinicalTrials.gov)	March 2003	13/2/2003	Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)	A Randomized Controlled Trial of Strategies for the Prevention of Accelerated Atherosclerosis in Systemic Lupus Erythematosus - A Pilot Study	Systemic Lupus Erythematosus;Lupus	Drug: pravastatin;Drug: aspirin;Drug: ramipril;Drug: Vitamins: B6, B12, and folate;Behavioral: heart health educational program	Brigham and Women's Hospital	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	18 Years	N/A	Both	150	Phase 2	United States

67. 多発性嚢胞腎

---

臨床試験数 : 216 /  薬物数 : 219 - (DrugBank : 50) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04284657 (ClinicalTrials.gov)	January 30, 2019	11/4/2019	Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease	Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease	Autosomal Dominant Polycystic Kidney Disease	Drug: Pravastatin;Drug: sodium citrate	University of Southern California	NULL	Enrolling by invitation	18 Years	N/A	All	30	Phase 2	United States
2	NCT03273413 (ClinicalTrials.gov)	August 31, 2017	1/9/2017	Statin Therapy in Patients With Early Stage ADPKD	Statin Therapy in Patients With Early Stage ADPKD	ADPKD;Autosomal Dominant Polycystic Kidney	Drug: Pravastatin;Drug: Placebo	University of Colorado, Denver	NULL	Recruiting	25 Years	60 Years	All	200	Phase 4	United States
3	NCT00456365 (ClinicalTrials.gov)	November 2006	12/3/2007	Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease	Polycystic Kidney, Autosomal Dominant	Drug: pravastatin;Drug: Placebo	University of Colorado, Denver	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	8 Years	22 Years	All	110	Phase 3	United States

79. 家族性高コレステロール血症（ホモ接合体）

---

臨床試験数 : 142 /  薬物数 : 114 - (DrugBank : 29) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 18

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03510715 (ClinicalTrials.gov)	August 31, 2018	18/4/2018	An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia	An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia	Hypercholesterolemia	Drug: Alirocumab SAR236553 (REGN727);Drug: Rosuvastatin;Drug: Ezetimibe;Drug: Cholestyramine;Drug: Nicotinic acid;Drug: Fenofibrate;Drug: Omega-3 fatty acids;Drug: Atorvastatin;Drug: Simvastatin;Drug: Fluvastatin;Drug: Pravastatin;Drug: Lovastatin	Sanofi	Regeneron Pharmaceuticals	Completed	8 Years	17 Years	All	18	Phase 3	Brazil;Canada;Denmark;Mexico;Netherlands;Russian Federation;Slovenia;Spain;Taiwan;Turkey;Austria;France;Italy;Norway;United States

96. クローン病

---

臨床試験数 : 2,400 /  薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00599625 (ClinicalTrials.gov)	October 2004	26/12/2007	Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study	Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study	Crohn's Disease	Drug: Pravastatin	University of Virginia	American College of Gastroenterology	Recruiting	18 Years	65 Years	Both	40	N/A	United States

164. 眼皮膚白皮症

---

臨床試験数 : 15 /  薬物数 : 57 - (DrugBank : 34) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00467831 (ClinicalTrials.gov)	April 2007	28/4/2007	Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome	Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome	Hermansky-Pudlak Syndrome (HPS);Pulmonary Fibrosis;Oculocutaneous Albinism;Platelet Storage Pool Deficiency;Metabolic Disease	Drug: Losartan;Drug: Zileuton;Drug: N-Acetylcysteine;Drug: Pravastatin;Drug: Erythromycin	National Human Genome Research Institute (NHGRI)	NULL	Terminated	18 Years	70 Years	All	3	Phase 1/Phase 2	United States

265. 脂肪萎縮症

---

臨床試験数 : 116 /  薬物数 : 170 - (DrugBank : 61) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 97

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00227500 (ClinicalTrials.gov)	July 2001	27/9/2005	Pravastatin for Hyperlipidaemia in HIV.	A Randomised, Double-Blind Study of Pravastatin for the Treatment of Hyperlipidaemia in Patients With HIV	HIV Infections;Lipid Metabolism;Glucose Metabolism;Metabolic Abnormality;Lipodystrophy;Cardiovascular Disease	Drug: Pravastatin	Kirby Institute	The University of New South Wales;National Heart, Lung, and Blood Institute (NHLBI);Garvan Institute of Medical Research;St Vincent's Hospital, Sydney	Completed	18 Years	N/A	Both	40	Phase 4	Australia
2	NCT00017758 (ClinicalTrials.gov)	June 2001	11/6/2001	The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs	The Effect of Efavirenz and Nelfinavir on the Pharmacokinetics of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors	HIV Infections;HIV Seronegativity;Lipodystrophy	Drug: Pravastatin sodium;Drug: Simvastatin;Drug: Atorvastatin calcium;Drug: Nelfinavir mesylate;Drug: Efavirenz	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	18 Years	60 Years	Both	56	Phase 1	United States
3	NCT00006412 (ClinicalTrials.gov)	October 25, 2000	13/10/2000	Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids	A Prospective, Multicenter, Randomized Trial Comparing the Efficacy and Safety of Fenofibrate Versus Pravastatin in HIV-Infected Subjects With Lipid Abnormalities	HIV Infections;Lipodystrophy	Drug: Pravastatin sodium;Drug: Fenofibrate	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	18 Years	N/A	All	630	Phase 3	United States;Puerto Rico

333. ハッチンソン・ギルフォード症候群

---

臨床試験数 : 7 /  薬物数 : 8 - (DrugBank : 3) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 6

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00916747 (ClinicalTrials.gov)	August 2009	5/6/2009	Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria	An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid Laminopathies	Progeria	Drug: Lonafarnib, Zoledronic Acid, and Pravastatin	Boston Children's Hospital	Schering-Plough;Merck Sharp & Dohme Corp.;Eiger BioPharmaceuticals	Active, not recruiting	N/A	N/A	All	85	Phase 2	United States
2	NCT00879034 (ClinicalTrials.gov)	March 2009	8/4/2009	A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria	A Phase II Pilot Study of Zoledronic Acid, Pravastatin, and Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies	Progeria;Hutchinson-Gilford Syndrome	Drug: Lonafarnib;Drug: Zoledronic Acid;Drug: Pravastatin	Boston Children's Hospital	Dana-Farber Cancer Institute;Brigham and Women's Hospital;Schering-Plough	Completed	N/A	N/A	All	5	Phase 2	United States
3	NCT00731016 (ClinicalTrials.gov)	October 2008	1/8/2008	Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid	Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid	Hutchinson-Gilford Progeria Syndrome	Drug: Zoledronic acid, pravastatin	Assistance Publique Hopitaux De Marseille	NULL	Completed	3 Years	N/A	Both	15	Phase 2	France

先頭へ